Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Actavis Group
The US Supreme Court has turned down a request by Teva’s Actavis to review a ruling that upheld a patent protecting Nalpropion’s Contrave until 2030, despite the generics firm pointing out that the exact terms of a patent claim were not present in its specification.
The US FDA finds metformin meets NDMA impurity threshold and urges diabetics to continue taking it.
Norway becomes the latest country to reverse-switch diclofenac in response to a 2018 study linking low doses of the drug to cardiovascular adverse events.
Oral diclofenac will no longer be available without a prescription in Sweden after the national drug regulator judged that the potential adverse event risks were too high to justify continued OTC supply. Products from GSK and Mylan will be affected by the decision.